White Round
Arrow Left
White Round
Arrow Right

E-series publications

The glycol ethers group contributed to a publication by Jeff Kelsey on available literature and data on endocrine disrupting properties of the E-series glycol ethers (EGE). The article called “Ethylene oxide derived glycol ethers: A review of the alkyl glycol ethers potential to cause endocrine disruption” was published in March in “Regulatory Toxicology and Pharmacology”. The extensive analysis done shows that there appears to be no significant evidence to support other published claims that EGE disrupt the endocrine system.

A similar article is being prepared for the P-series glycol ethers.

Download a copy of the article

EGME

As you could read in our newsflash from March, EGME has not been proposed by the Commission to be included in annexe XIV of REACH, which would have triggered authorisation. The REACH Committee endorsed this vote, and there were also no objections from the Parliament or the Council.

Following Council decisions, EGME is one of the 12 substances moved from the Chemical Agent Directive (CAD) in order to include reprotoxic substances in the Carcinogenic & Mutagenic Directive (CMD). It can be expected that the existing iOELv will be transferred in Annex 3 of the (now) Carcinogenic & Mutagenic & Reprotoxins Directive (CMRD) as binding OEL.

EGME Newsflash

EGBE

The 18th ATP (Commission Delegated regulation (EU) 2022/692) to the CLP was adopted on 16th February 2022 and published on 3rd May 2022 to implement the change. The regulation  includes EGBE classified in the Acute Toxicity Category 3 (inhalation; H331) and will apply from 1st December 2023. 

Manufacturers strongly disagreed with the proposed classification, and OSPA submitted detailed arguments to this effect to the two RAC and CARACAL meetings where the topic was discussed. Unfortunately, these were not accepted.  

On the other impacts of this classification, for instance, on SEVESO-III requirements, we have published a FAQ document on the ESIG website – ‘Frequently Answered Questions’ sheet providing detailed answers and facts to customers of EGBE on the classification of EGBE as Acute Toxicity Category 3 (inhalation; H331). 

EGBE FAQs